| Literature DB >> 34111059 |
Athalia Christie1, S Jane Henley1, Linda Mattocks1, Robyn Fernando1, Amy Lansky1, Farida B Ahmad1, Jennifer Adjemian1, Robert N Anderson1, Alison M Binder1, Kelly Carey1, Deborah L Dee1, Taylor Dias1, William M Duck1, Denise M Gaughan1, Brianna Casey Lyons1, A D McNaghten1, Meeyoung M Park1, Hannah Reses1, Loren Rodgers1, Katharina Van Santen1, David Walker1, Michael J Beach1.
Abstract
Throughout the COVID-19 pandemic, older U.S. adults have been at increased risk for severe COVID-19-associated illness and death (1). On December 14, 2020, the United States began a nationwide vaccination campaign after the Food and Drug Administration's Emergency Use Authorization of Pfizer-BioNTech COVID-19 vaccine. The Advisory Committee on Immunization Practices (ACIP) recommended prioritizing health care personnel and residents of long-term care facilities, followed by essential workers and persons at risk for severe illness, including adults aged ≥65 years, in the early phases of the vaccination program (2). By May 1, 2021, 82%, 63%, and 42% of persons aged ≥65, 50-64, and 18-49 years, respectively, had received ≥1 COVID-19 vaccine dose. CDC calculated the rates of COVID-19 cases, emergency department (ED) visits, hospital admissions, and deaths by age group during November 29-December 12, 2020 (prevaccine) and April 18-May 1, 2021. The rate ratios comparing the oldest age groups (≥70 years for hospital admissions; ≥65 years for other measures) with adults aged 18-49 years were 40%, 59%, 65%, and 66% lower, respectively, in the latter period. These differential declines are likely due, in part, to higher COVID-19 vaccination coverage among older adults, highlighting the potential benefits of rapidly increasing vaccination coverage.Entities:
Year: 2021 PMID: 34111059 DOI: 10.15585/mmwr.mm7023e2
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586